Efficacy and safety of pamapimod in patients with active rheumatoid arthritis receiving stable methotrexate therapy
Authors:
- 1 February 2010
- journal article
- research article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 69 (2) , 364-367
Abstract
Objective: To determine the efficacy and safety of pamapimod in adult patients with active rheumatoid arthritis (RA) who had an inadequate clinical response to methotrexate (MTX). Methods: Patients receiving stable doses of MTX were randomised to one of six dose groups and received 12 weeks of double-blind pamapimod (up to 300 mg once daily) or matching placebo. The primary efficacy measure was the proportion of patients with ⩾20% improvement in RA based on the American College of Rheumatology criteria (ACR20) at 12 weeks. Secondary measures were ACR50, Disease Activity Score (DAS)/European League Against Rheumatism (EULAR) responses and the individual ACR core set of parameters. Safety measures included adverse events (AEs), laboratory testing and immunology assessments. Results: On a background of MTX, the percentage of patients with an ACR20 response at week 12 in the pamapimod groups (31% to 43%) was not significantly different from placebo (34%). Secondary efficacy end points showed a similar pattern. AEs were typically mild and included infections, gastrointestinal disturbances, dizziness and rashes; AEs resulting in discontinuation of study drug were primarily attributed to infections. Conclusion: In patients with active RA receiving stable doses of MTX, pamapimod showed non-significant improvement in efficacy outcomes compared to placebo.Keywords
This publication has 13 references indexed in Scilit:
- Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double‐blind, methotrexate‐controlled study of patients with active rheumatoid arthritisArthritis & Rheumatism, 2009
- Inhibition of p38: Has the fat lady sung?Arthritis & Rheumatism, 2009
- Pamapimod, a Novel p38 Mitogen-Activated Protein Kinase Inhibitor: Preclinical Analysis of Efficacy and SelectivityThe Journal of Pharmacology and Experimental Therapeutics, 2008
- Differential tissue expression and activation of p38 MAPK α, β, γ, and δ isoforms in rheumatoid arthritisArthritis & Rheumatism, 2006
- Oral p38 Mitogen-Activated Protein Kinase Inhibition With BIRB 796 for Active Crohn’s Disease: A Randomized, Double-Blind, Placebo-Controlled TrialClinical Gastroenterology and Hepatology, 2006
- Kinase Inhibitor-Induced PustulesDermatology, 2005
- p38 Mitogen-Activated Protein Kinase Inhibitors— Mechanisms and Therapeutic PotentialsPharmacology & Therapeutics, 1999
- Induction of Cyclooxygenase-2 by the Activated MEKK1 → SEK1/MKK4 → p38 Mitogen-activated Protein Kinase PathwayJournal of Biological Chemistry, 1998
- The American college of rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trialsArthritis & Rheumatism, 1993
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988